FDA clears Pfizer’s potential eczema blockbuster
Pfizer’s Eucrisa has been cleared by the US Food and Drug Administration as a treatment for mild to moderate atopic dermatitis in patients two years of age and older.
Read More
Tag: Anacor
Pfizer completes $5.2bn acquisition of Anacor
Pfizer has completed its acquisition of Silicon Valley biotech group Anacor securing access to its flagship non-steroidal topical PDE4 inhibitor crisaborole.
Read More
Pfizer to spend $4.2bn on Anacor
Pfizer is spending around $4.2 billion on the purchase of Anacor Pharmaceuticals, thus securing access to the firm’s flagship non-steroidal topical PDE4 inhibitor crisaborole
Read More
- UCB and Cancer Research UK form expanded alliance to advance novel cancer therapies
- Calla Lily Clinical Care begins dosing in trial of intravaginal platform for threatened miscarriage
- Palisade Bio reports phase 1a/b data showing colon‑targeted exposure
- MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
- Myomaker Bio unveils lab‑grown human muscle platform to transform drug testing
